SCHEMBL3137205

SCHEMBL3137205

CC(CO)=C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
OPRM1 P35372 6/20 0.44
CYP2D6 P10635 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
DRD1 P21728 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HRH1 P35367 1/20 0.44
DRD3 P35462 1/20 0.44
HTR2B P41595 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KCNH2 Q12809 1/20 0.44
MEN1 O00255 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29785585 0.80 OPRM1 (0.42) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL29785622 0.80 OPRM1 (0.43) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL3135687 0.79 ATM (0.42) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL3134253 0.79 CACNA2D1 (0.43) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL29785578 0.78 OPRM1 (0.43) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL3132074 0.76 DRD2 (0.49) KMT2ADRD3MEN1ALDH1A1CYP3A4
SCHEMBL28817629 0.76 KMT2A (0.46) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL28817670 0.76 KMT2A (0.46) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL28817632 0.76 KMT2A (0.46) KMT2AOPRM1CYP2D6CHRM2CHRM4
SCHEMBL29785546 0.74 KMT2A (0.49) KMT2ACYP2D6MEN1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114763357-B Indolopyrimidine tricyclic compound and preparation method and application thereof 中国科学院上海药物研究所 2024-06-18 CN disclosed
WO-2010056633-A2 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2010-05-20 WO disclosed
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2009-06-18 US disclosed
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES NQO2, QRFPR, NQO1 KMT2A 1652/4885OPRM1 439/4885CYP2D6 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.